In terms of genomics, our cohort had a distinctive mutational profile with a predominance of TET2, DNMT3A, and TP53 mutations, which differs from the de novo leukemia profile2 and we show that 94% of the patients had actionable mutations. The gene discussed is DNMT3A; the disease is leukemia.